Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

How 11 States Attracted the Smartest Scientists, Research

Washington, DC, August 13, 2013The Washington Post reports that nations have long competed to lead the world in scientific achievement.  The United States, for example, now spends nearly 3 percent of its GDP on basic R&D.  But the benefits of public spending on research are also becoming clear at the state level.

A new paper published by the UC-Berkeley economist Enrico Moretti and Daniel Wilson of the San Francisco Federal Reserve finds that states that created tax or other incentives for the biotech industry over the last 20 years have experienced tremendous growth in the number of “star” scientists inhabiting those states.

Star scientists, the authors explain, are “exceptionally prolific patenters” who account for the top 5 percent of all biotech patent filers nationally over the past decade.  

The Washington Post reports that states that adopted biotech subsidies (there are about 11 of them, according to the paper) increased the number of star scientists within their boundaries by 15 percent.

Employment in related sectors also improved — in one pharmaceutical sub-industry, by as much as 31 percent.  

The cascading effects of bringing in new scientists led to indirect booms for retail, real estate and construction.  The construction industry in particular saw employment gains of about 16 percent after biotech subsidies took effect.

The subsidies proved pretty effective at getting star scientists to relocate. But how good were they at converting people into new star scientists — those who weren’t in the top 5 percent before?

Not only did subsidy-adopting states have more stars than non-adopters, the study discovered — 7.9 per million vs. 3.5 per million — but they also had 0.6 per million more new stars, an indication that subsidy-adopting states were actually helping their biotech industries grow natively from within.

For the full Washington Post story, click here.